The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Pharmacological characterization of designer cathinones in vitro
Open accessAbstract
Background and Purpose: Designer β‐keto amphetamines (e.g. cathinones, ‘bath salts’ and ‘research chemicals’) have become popular recreational drugs, but their pharmacology is poorly characterized. Experimental Approach: We determined the potencies of cathinones to inhibit DA,NA and 5‐HT transport into transporter‐transfected HEK 293 cells,DA and 5‐HT efflux from monoamine‐preloaded cells, and monoamine receptor binding affinity. Key Results: Mephedrone, methylone, ethylone, butylone and naphyrone acted as non‐selective monoamine uptake inhibitors, similar to cocaine. Mephedrone, methylone, ethylone and butylone also induced the release of 5‐HT, similar to 3,4‐methylenedioxymethamphetamine (MDMA, ecstasy) and other entactogens. Cathinone, methcathinone and flephedrone, similar to amphetamine and methamphetamine, acted as preferential DA and NA uptake inhibitors and induced the release of DA. Pyrovalerone and 3,4‐methylenedioxypyrovalerone (MDPV) were highly potent and selective DA and NA transporter inhibitors but unlike amphetamines did not evoke the release of monoamines. The non‐β‐keto amphetamines are trace amine‐associated receptor 1 ligands, whereas the cathinones are not. All the cathinones showed high blood–brain barrier permeability in an in vitro model; mephedrone and MDPV exhibited particularly high permeability. Conclusions and Implications: Cathinones have considerable pharmacological differences that form the basis of their suggested classification into three groups. The predominant action of all cathinones on the DA transporter is probably associated with a considerable risk of addiction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Martin, W. R., Sloan, J. W., Sapira, J. D., & Jasinski, D. R. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971122part1245 · Cited by 943
Pharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939
Rothman, R. B., Baumann, M. H., Dersch, C. M., Romero, D. V., Rice, K. C., Carroll, F. I., & Partilla, J. S. (2001) · Synapse · doi:10.1002/1098-2396(20010101)39:1<32::aid-syn5>3.0.co;2-3 · Cited by 938
Ghose, A. K., Viswanadhan, V. N., & Wendoloski, J. J. (1998) · The Journal of Physical Chemistry A · doi:10.1021/jp980230o · Cited by 790
Spiller, H. A., Ryan, M. L., Weston, R. G., & Jansen, J. (2011) · Clinical Toxicology · doi:10.3109/15563650.2011.590812 · Cited by 522
Baumann, M. H., Ayestas, M. A., Partilla, J. S., Sink, J. R., Shulgin, A. T., Daley, P. F., Brandt, S. D., Rothman, R. B., Ruoho, A. E., & Cozzi, N. V. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.304 · Cited by 439
Meltzer, P. C., Butler, D., Deschamps, J. R., & Madras, B. K. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050797a · Cited by 411
In vitro model for evaluating drug transport across the blood–brain barrier
Cecchelli, R., Dehouck, B., Descamps, L., Fenart, L., Buée-Scherrer, V, Duhem, C., Lundquist, S., Rentfel, M., Torpier, G., & Dehouck, M. P. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00083-0 · Cited by 383
Revel, F. G., Moreau, J.-L., Gainetdinov, R. R., Bradaia, A., Sotnikova, T. D., Mory, R., Durkin, S., Zbinden, K. G., Norcross, R., Meyer, C. A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103029108 · Cited by 364
Self-citationGender differences in the subjective effects of MDMA
Liechti, M. E., Gamma, A., & Vollenweider, F. X. (2001) · Psychopharmacology · doi:10.1007/s002130000648 · Cited by 360
Self-citationTrace Amine-Associated Receptor 1 Modulates Dopaminergic Activity
Lindemann, L., Meyer, C. A., Jeanneau, K., Bradaia, A., Ozmen, L., Bluethmann, H., Bettler, B., Wettstein, J. G., Borroni, E., Moreau, J.-L., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.132647 · Cited by 348
Self-citationCathinone derivatives: A review of their chemistry, pharmacology and toxicology
Kelly, J. P. (2011) · Drug Testing and Analysis · doi:10.1002/dta.313 · Cited by 346
Kehr, J., Ichinose, F., Yoshitake, S., Goiny, M., Sievertsson, T., Nyberg, F., & Yoshitake, T. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01499.x · Cited by 312
The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain
Nagai, F., Nonaka, R., & Satoh Hisashi Kamimura, K. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.075 · Cited by 279
Liechti, M. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00148-7 · Cited by 248
Self-citationLiechti, M. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00126-3 · Cited by 245 · cited 2×
“Direct interactions between MDMA and 5-HT2 receptors rather than indirect agonist effects via 5-HT release have been suggested to contribute to MDMA-induced excitation and hallucinogen-like perceptual alterations at higher doses (Liechti et al., 2000b; 2001).”
BackgroundSelf-citationA web-based survey on mephedrone
Carhart-Harris, R. L., King, L. A., & Nutt, D. J. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.02.011 · Cited by 244
4-Methylmethcathinone (Mephedrone): Neuropharmacological Effects of a Designer Stimulant of Abuse
Hadlock, G. C., Webb, K. M., McFadden, L. M., Chu, P. W., Ellis, J. D., Allen, S. C., Andrenyak, D. M., Vieira-Brock, P. L., German, C. L., Conrad, K. M., et al. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.184119 · Cited by 242
Pharmacodynamics and pharmacokinetics of khat: A controlled study
Widler, P., Mathys, K., Brenneisen, R., Kalix, P., & Fisch, H.-U. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.69 · Cited by 232
Instability of the ecstasy market and a new kid on the block: mephedrone
Brunt, T. M., Poortman, A., Niesink, R. J., & van den Brink, W. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110378370 · Cited by 215
Wee, S., Anderson, K. G., Baumann, M. H., Rothman, R. B., Blough, B. E., & Woolverton, W. L. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.080101 · Cited by 211
Verrico, C. D., Miller, G. M., & Madras, B. K. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0174-5 · Cited by 205
Pharmacological properties of the stimulant khat
Kalix, P. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90057-9 · Cited by 197
López‐Arnau, R., Martínez‐Clemente, J., Pubill, D., Escubedo, E., & Camarasa, J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01998.x · Cited by 196
Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines
Cozzi, N. V., Sievert, M. K., Shulgin, A. T., Jacob, P., & Ruoho, A. E. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00538-5 · Cited by 194
Steele, T. D., Nichols, D. E., & Yim, G. K. W. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90594-6 · Cited by 180
Hysek, C. M., Simmler, L. D., Nicola, V. G., Vischer, N., Donzelli, M., Krähenbühl, S., Grouzmann, E., Huwyler, J., Hoener, M. C., & Liechti, M. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036476 · Cited by 178
Self-citationWatterson, L. R., Kufahl, P. R., Nemirovsky, N. E., Sewalia, K., Grabenauer, M., Thomas, B. F., Marusich, J. A., Wegner, S., & Olive, M. F. (2014) · Addiction Biology · doi:10.1111/j.1369-1600.2012.00474.x · Cited by 176
Coppola, M., & Mondola, R. (2011) · Toxicology Letters · doi:10.1016/j.toxlet.2011.10.002 · Cited by 163
Gudelsky, G. A., Yamamoto, B. K., & Nash, J. F. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90669-6 · Cited by 162
Sano, Y., Shimizu, F., Abe, M., Maeda, T., Kashiwamura, Y., Ohtsuki, S., Terasaki, T., Obinata, M., Kajiwara, K., Fujii, M., et al. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22232 · Cited by 140
Fleckenstein, A. E., Haughey, H. M., Metzger, R. R., Kokoshka, J. M., Riddle, E. L., Hanson, J. E., Gibb, J. W., & Hanson, G. R. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00588-9 · Cited by 136
Rothman, R. B., & Baumann, M. H. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1369.064 · Cited by 136
Interaction of mephedrone with dopamine and serotonin targets in rats
Martínez-Clemente, J., Escubedo, E., Pubill, D., & Camarasa, J. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.009 · Cited by 128
Methcathinone: A new and potent amphetamine-like agent
Glennon, R. A., Yousif, M., Naiman, N. A., & Kalix, P. (1987) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(87)90164-x · Cited by 125
Cathinone: An Investigation of Several N-Alkyl and Methylenedioxy-Substituted Analogs
Cason, T. A. D., Young, R., & Glennon, R. A. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(97)00323-7 · Cited by 125
Lyon, R. A., Glennon, R., & Titeler, M. (1986) · Psychopharmacology · doi:10.1007/bf00178519 · Cited by 121
Baumann, M. H., Clark, R. D., Woolverton, W. L., Wee, S., Blough, B. E., & Rothman, R. B. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.176271 · Cited by 110
A Receptor Mechanism for Methamphetamine Action in Dopamine Transporter Regulation in Brain
Xie, Z., & Miller, G. M. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.153775 · Cited by 108
Cara, B. D., Maggio, R., Aloisi, G., Rivet, J., Lundius, E. G., Yoshitake, T., Svenningsson, P., Brocco, M., Gobert, A., de Groote, L., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.2502-11.2011 · Cited by 100
Scholze, P., Zwach, J., Kattinger, A., Pifl, C., Singer, E. A., & Sitte, H. H. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39309-7 · Cited by 99
Thornton, S. L., Gerona, R. R. L., & Tomaszewski, C. (2012) · Journal of Medical Toxicology · doi:10.1007/s13181-012-0232-4 · Cited by 93
Motbey, C. P., Hunt, G. E., Bowen, M. T., Artiss, S., & McGregor, I. S. (2011) · Addiction Biology · doi:10.1111/j.1369-1600.2011.00384.x · Cited by 93
Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans
Hysek, C. M., Schmid, Y., Rickli, A., Simmler, L. D., Donzelli, M., Grouzmann, E., & Liechti, M. E. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01936.x · Cited by 92
Self-citationPREFERENCE IN RHESUS MONKEYS GIVEN A CHOICE BETWEEN COCAINE AND d,l‐CATHINONE
Woolverton, W. L., & Johanson, C. E. (1984) · Journal of the Experimental Analysis of Behavior · doi:10.1901/jeab.1984.41-35 · Cited by 90
Hysek, C. M., Brugger, R., Simmler, L. D., Bruggisser, M., Donzelli, M., Grouzmann, E., Hoener, M. C., & Liechti, M. E. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.188425 · Cited by 73
Self-citationNewton, T. F., Garza, R. D. L., Brown, G., Kosten, T. R., Mahoney, J. J., & Haile, C. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030854 · Cited by 59
A comparison of the behavioral effects of l- and dl-cathinone and d-amphetamine.
Johanson, C. E., & Schuster, C. R. (1981) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32809-0 · Cited by 55
Acquas, E., Pisanu, A., Spiga, S., Plumitallo, A., Zernig, G., & Chiara, G. D. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04451.x · Cited by 53
Derungs, A., Schietzel, S., Meyer, M. R., Maurer, H. H., Krähenbühl, S., & Liechti, M. E. (2011) · Clinical Toxicology · doi:10.3109/15563650.2011.592838 · Cited by 52
Self-citationAbuse Liability Profile of Three Substituted Tryptamines
Gatch, M. B., Forster, M. J., Janowsky, A. J., & Eshleman, A. J. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.179705 · Cited by 45
Sano, Y., Kashiwamura, Y., Abe, M., Dieu, L., Huwyler, J., Shimizu, F., Haruki, H., Maeda, T., Saito, K., Tasaki, A., et al. (2012) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12001 · Cited by 37
Self-citationMontgomery, T., Buon, C., Eibauer, S., Guiry, P. J., KEENAN, A. K., & McBean, G. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707473 · Cited by 33
Methcathinone is a Substrate for the Serotonin Uptake Transporter*
Cozzi, N. V., & Foley, K. F. (2003) · Pharmacology & Toxicology · doi:10.1046/j.1600-0773.2003.pto930504.x · Cited by 31
Intravenous self-administration of cathinone by rats.
Gosnell, B. A., Yracheta, J., Bell, S., & Lane, K. E. (1996) · PubMed · Cited by 31
Research works printed but not linked: 4
- Aarde SA, 2011, Behavioral and termoregulatory effects of novel cathinone derivative drugs 4‐MMC and MDPV, Neuropsychopharmacology, 36, S441
- 10.1016/j.drugalcdep.2012.05.011 · doi:10.1016/j.drugalcdep.2012.05.011
- Watteron LR, 2011, Potent reinforcing effects of the synthetic cathinone methylenedioxypyrovalerone (MDPV) in rats, Neuropsychopharmacology, 36, S440
- 10.1111/j.1360-0443.2010.03130.x · doi:10.1111/j.1360-0443.2010.03130.x
Cited by
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.05.001 · Cited by 379
Self-citationKhat and synthetic cathinones: a review
Valente, M. J., Guedes de Pinho, P., de Lourdes Bastos, M., Carvalho, F., & Carvalho, M. (2014) · Archives of Toxicology · doi:10.1007/s00204-013-1163-9 · Cited by 337
Oxytocin-dependent reopening of a social reward learning critical period with MDMA
Nardou, R., Lewis, E. M., Rothhaas, R., Xu, R., Yang, A., Boyden, E., & Dölen, G. (2019) · Nature · doi:10.1038/s41586-019-1075-9 · Cited by 334
Designer drugs: mechanism of action and adverse effects
Luethi, D., & Liechti, M. E. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02693-7 · Cited by 262
Self-citationSerotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions
Scotton, W. J., Hill, L. J., Williams, A. C., & Barnes, N. M. (2019) · International Journal of Tryptophan Research · doi:10.1177/1178646919873925 · Cited by 267
Metadata
- Authors
- Simmler, L., Buser, T., Donzelli, M., Schramm, Y., Dieu, L., Huwyler, J., Chaboz, S., Hoener, M., & Liechti, M.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2012-12-20
- Volume
- 168
- Issue
- 2
- Pages
- 458-470
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1572907996
- Cited by
- 672
- References
- 57
- FWCI
- 55.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.